aBSI provides detection and quantification of lesions for evaluation of Prostate Cancer Progression. EXINI Automated Bone Index (aBSI) marks the lesions and quantifies the disease burden.
Images shown for illustrative purposes only.
~29% and ~21% improved nodules detection
Riverain's AI suppression technology removes structures that can camouflage cancer and lung disease. 1,2
~26% and ~20% faster nodule search time
ClearRead CT technology helps radiologists see through the complexity to better detect abnormalities.1,2
Higher inter-reader agreement rates2
For CalanticTM software version 1.0.0 and older versions, no prior study will be examined.
Number of frames (0028,0008) must be 1 or 2
Number of slices (0054,0081) must be 1 or 2
Pixel spacing (0028,0030) must be ≥ 1.8 mm/pixel and ≤ 2.8 mm/pixel
The anterior and posterior images may be stored as either two different series (two files with different Series Instance UID) or as one multi-frame series (one file) containing two frames.
Image pixel data should be in the 16-bit range. Images with pixels ranging from 0 to 255 (8- bit) are not sufficient.
Picture Archiving and Communications System (PACS) tool, clinical application for oncology, including lesion marking and quantitative analysis (Calculation of Bone Scan Index (BSI)).
Currently not made available with Calantic Viewer. Separately distributed by Bayer.
EU risk class and CE marking
aBSI has CE marking (CE0123) and risk class IIa.
No contraindications given.
Trained healthcare professionals and researchers.
BSI should not be reported:
- for patients with non-metastatic prostate cancer (M0),
- if image input requirements are not fulfilled,
- if atlas does not match the imaged skeleton,
- if the image(s) contains a large hotspot that includes the urinary bladder